EUCTR2011-000169-10-IT进行中（未招募）不适用
A Phase II, Randomised Pilot Study to Evaluate the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo - Phase II Vitiligo Pilot Study
CLINUVEL PHARMACUETICALS LTD.0 个研究点目标入组 60 人开始时间: 2012年3月5日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male and female subjects with a confirmed diagnosis of nonsegmental vitiligo with 15% to 50% of total body surface involvement •Stable or slowly progressive vitiligo over a 3-month period •Aged 18 or more •Fitzpatrick skin types III-VI •Willing and able to comply with the conditions specified in this protocol and study procedures in the opinion of the Investigator •Providing written Informed Consent prior to the performance of any study-specific procedure
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •Fitzpatrick skin types I-II •Vitiligo involving the hands and feet only •Extensive leukotrichia, in the opinion of the Investigator •Vitiligo of more than 5 years duration • Previous treatment with NB-UVB within 6 months prior to the Screening Visit • Patient not responsive to previous NB-UVB treatment, defined as a patient who has undergone at least 30 NB-UVB sessions with no or minimal clinically relevant pigmentary response, in the opinion of the Investigator •Allergy to afamelanotide or the polymer contained in the implant or to lignocaine/lidocaine or other local anaesthetic to be used during the administration of the implant •Previous treatment with topical immunomodulators (corticosteroids, calcineurin inhibitors) for vitiligo within 4 weeks prior to the Screening Visit •History of photosensitivity disorders •Claustrophobia •History of photosensitive lupus •Any active and/or unstable autoimmune disease judged to be clinically significant by the Investigator • Any disorder associated with an immune deficiency eg infections with EBV or CMV • Diagnosed with HIV/AIDS, or Hepatitis B or C •History of melanoma or lentigo maligna • Patients with a family history of melanoma in a first degree relative •History of dysplastic nevus syndrome • History of malignant or pre-malignant skin lesions • Patients with a large number of nevi or patients having more than 5 atypical nevi •Any skin disease that may interfere with the study evaluation •Any evidence of organ dysfunction or deviation from normal in clinical or laboratory determinations judged to be clinically significant by the Investigator •History of systemic or psychiatric disease judged to be clinically significant by the Investigator and which may interfere with the study evaluation •Female who is pregnant (confirmed by positive β-HCG pregnancy test) or lactating •Female of child-bearing potential (pre-menopausal, not surgically sterile) not using adequate contraceptive measures (i.e. oral contraceptives, diaphragm plus spermicide, intrauterine device) during the trial and for a period of three months thereafter •Sexually active man with a partner of child-bearing potential not using barrier contraception during the trial and for a period of three months hereafter •Participation in a clinical trial for an investigational agent within 30 days prior to the Screening Visit •Use of any prior and concomitant therapy which may interfere with the objective of the study, including drugs that cause photosensitivity or skin pigmentation within 60 days prior to the Screening Visit •Subjects assessed as not suitable for the study in the opinion of the Investigator
研究者
相似试验
进行中（未招募）
1 期
A trial examining the effects of alteplase in patients with severe respiratory failure.EUCTR2010-024377-40-ATMedizinische Universität Wien, UniKlinik für Klinische Pharmakologie
已完成
2 期
A randomized phase II study for the evaluation of T cell depleted non-myeloablative allogeneic stem cell transplantation followed by early consolidation with lenalidomide or lenalidomide combined with bortezomib and subsequent DLI for patients with multiple myeloma in progression or relapse following first line therapyKahlers disease10035227Multiple MyelomaNL-OMON36688HOVO110
进行中（未招募）
不适用
A phase II, open, controlled study to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals AS25 adjuvanted influenza vaccine (FluAS25) in elderly adults (=67 years) previously vaccinated in the FluAS25-014 clinical trial with the same candidate vaccine. Fluarix™ (known as a-Rix® in Belgium) will be used as reference. - FluAS25-018 EXT 001 Y3Immunization against influenza in male and female subjects aged 67 years and older.EUCTR2007-002881-36-BEGlaxoSmithKline Biologicals74
进行中（未招募）
不适用
A phase II, open, controlled study to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals AS25 adjuvanted influenza vaccine (FluAS25) in elderly adults (=66 years) previously vaccinated in the FluAS25-004 clinical trial with the same candidate vaccine. Fluarix™ (known as a-Rix in Belgium) administered in young (19-42 years) and elderly (=66 years) adults will be used as reference. - FluAS25-008 EXT:003 Y2Immunization against influenza in male and female subjects aged 66 years and older.EUCTR2007-002880-29-BEGlaxoSmithKline Biologicals
进行中（未招募）
不适用
A phase II, open, controlled study to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals AS25 adjuvanted influenza vaccine (FluAS25) in elderly adults previously vaccinated in FluAS25-003 clinical trial with the same candidate vaccine. Fluarix™ administered in young and elderly adults will be used as reference. - FluAS25-004Immunisation against influenza disease in an elderly population aged over 65 yearsEUCTR2006-003236-30-BEGlaxoSmithKline Biologicals